State-of-the-art treatments in non-Hodgkin's lymphoma

Research output: Contribution to journalReview articlepeer-review


The non-Hodgkin's lymphomas are a diverse group of disorders morphologically, immunologically, and clinically. It is estimated that lymphoma represents 4% of the new cancer diagnoses and 4% of the cancer deaths. Lymphoma ranks third in increases in cancer death rates since 1973. Classification schemes have been further refined reclassifying previously described entities, differentiating B and T-cell entities, and defining new entities. This review will focus on standard treatment approaches, new therapeutic approaches, and preclinical directions.

Original languageEnglish (US)
Pages (from-to)303-314
Number of pages12
JournalCancer Research Therapy and Control
Issue number3-4
StatePublished - Sep 29 1999


  • Anti-idiotypic antibodies
  • Monoclonal antibody therapy
  • Non-Hodgkin's lymphoma
  • Non-Hodgkins lymphoma chemotherapy
  • Purine analogues
  • Vaccine therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'State-of-the-art treatments in non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this